Loading...

Home
ETF
NAUT

NAUT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NAUT News

Nautilus Biotechnology Q4 2025 Earnings Call Highlights

Feb 26 2026seekingalpha

Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook

Feb 26 2026seekingalpha

BETA Technologies Upgraded to Buy by Jefferies Amid Potential Catalysts

Feb 22 2026Yahoo Finance

Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary

Oct 28 2025NASDAQ.COM

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

Oct 23 2025NASDAQ.COM

Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth

Sep 11 2025NASDAQ.COM

Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement

Sep 10 2025NASDAQ.COM

Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript

Aug 01 2025Newsfilter

Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 27 2025Newsfilter

Insider Purchase: CEO of $NAUT Buys 23,933 Shares

Mar 21 2025NASDAQ.COM

TD Cowen Reaffirms Their Buy Rating on Nautilus Biotechnolgy (NAUT)

Feb 28 2025Business Insider

Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

Dec 05 2024Benzinga

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award

Oct 31 2024Globenewswire

Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

Sep 17 2024Newsfilter

Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14 2024Newsfilter

Jefferies Assumes Nautilus Biotechnology at Hold, Lowers Price Target of $3

Jun 03 2024Benzinga